Rakesh Jhunjhunwala

Big opportunity to grow in US market: IKS Health CFO Nithya Balasubramanian

Rakesh Jhunjhunwala-backed IKS Health sees significant opportunity in the US healthcare market, as the government pushes reforms aimed at reducing soaring healthcare costs

Jhunjhunwala family-backed firm's stock slides 4% after large trades

Inventurus Knowledge Solutions shares fell after a 1.5% stake changed hands in a block deal; buyer and seller unknown

Star Health hits new low post Q3 nos, down 53% from IPO price; time to buy?

Technically, this Rakesh Jhunjhunwala-backed stock is seen headed towards its monthly trend line support; break of the same can invite a further fall at the counter. Check key levels here.

Rekha Jhunjhunwala-backed Inventurus IPO to open on Dec 12; know more here

Unlisted shares of Inventurus Knowledge Solutions were trading at Rs 1,554 apiece in the grey market, reflecting a premium of Rs 225 or 16.93 percent over the upper price band of Rs 1,329

Role models like Rakesh Jhunjhunwala inspire new investors: Hiren Ved

Now, the focus has shifted from creating investor intent through education to enabling easy execution via digital channels

Jhunjhunwala Portfolio: This pharma stock has zoomed over 100% in 6 months

Shares of Jubilant Pharmova surged 12 per cent on the BSE in Friday's intra-day trade to hit a new high of Rs 1,169.55, in an otherwise subdued market.

Rekha Jhunjhunwala set to pocket Rs 106 cr from Baazar Style Retail IPO

Among those investors selling shares is Rekha Rakesh Jhunjhunwala, who owns 5,446,240 shares, representing a 7.69 per cent stake in the company

Tata Motors' DVR conversion plan gets shareholders' nod with 99.8% votes

The shareholder approval will pave the way for Tata Motors to convert its shares with DVR into ordinary shares and thereby simplify its capital structure

Tata powers Rekha Jhunjhunwala's portfolio in 2024; outperforms markets

Of top 10 companies in Rekha Jhunjhunwala's portfolio total 8 stocks have given positive returns; while Metro Brands and Fortis Healthcare recorded negative returns of 11 per cent and 4 per cent

Rekha Jhunjhunwala-owned stock zoomed 12% today; what's fuelling the rally?

Rekha Jhunjhunwala, wife of late ace investor Rakesh Jhunjhunwala, held a 4.8-per cent stake in Metro Brands at the end of December 2023

CAE signs deal with Akasa Air to train budget carrier's B737 Max pilots

Agreement gives Akasa Air 'access to world's best training facilities' for 15 years

This Rekha Jhunjhunwala-owned share nears Rs 1 trn mcap; plans stock split

Shares of Canara Bank hit multi-year high at Rs 550.50, as they rallied 6 per cent after the lender said its board will meet on February 26 to consider stock split.

Boeing wins order for 150 Max jets from Akasa amid recent mid-air blowout

Akasa Air, which began flying commercially less than two years ago, made a firm purchase for the 737 Max 10 and Max 8-200 planes to be delivered through 2032, the carrier announced

No adverse findings in Boeing 737 Max planes, says Akasa post-inspection

Akasa Air on Monday said it has completed a thorough inspection of its entire fleet of in-service Boeing 737 Max planes and that there are no adverse findings. The Directorate General of Civil Aviation (DGCA), on January 5, directed domestic airlines to immediately carry out inspection of emergency exits of all Boeing 737-8 Max planes in their fleets as an "abundant precautionary measure" in the wake of the Alaska Airlines incident. On January 4, an Alaska Airlines plane's outer section, including a window, fell off mid-air and the aircraft involved was Boeing 737-9 Max. In a statement on Monday, Akasa Air said subsequent to the guideline issued by DGCA, it has completed a thorough inspection of its entire fleet of in-service Boeing 737 Max aircraft. "We can confirm that there are no adverse findings. We can also confirm that there was no disruption to our operations during this time," it said. Akasa Air has 22 Max planes in its fleet. Currently, there are more than 40 Boeing 737-

Jhunjhunwala family-backed IKS Health acquires US tech firm for $200 mn

The combined company is forecast to have an annual revenue of over US$ 330 million (Rs 2,748 crore), as well as a global workforce of over 14,000 employees

This footwear stock in Jhujhuwala's kitty is now up 158% over IPO price

Shares of Metro Brands that boasts of Metro, Mochi, Walkaway, Crocs and Fitflop brands, hit a record high of Rs 1,292, rallied 15% in intra-day trade on the BSE.

Resignations have no impact on expansion, more pilots joining: Akasa CEO

Promoted by family of the late investor Rakesh Jhunjhunwala, Akasa is planning to add more aircraft to its fleet and take it to 28 by March 2024 and add 10-12 planes every year for the next few years

Jhunjhunwala family-backed Concord Biotech gains 27% on market debut

The strong listing follows healthy demand for the shares of Gujarat-based bulk drug maker in its Rs 1,551-crore initial public offering (IPO)

Concord Biotech lists at 21% premium over its issue price

The shares of the biopharma company listed at Rs 900, a 21 per cent higher against its issue price of Rs 741 per share on the National Stock Exchange and BSE on Friday.

Jhunjhunwala-backed Concord Biotech IPO opens today: What do analysts say?

Concord Biotech IPO: The stock is commanding a 20 per cent premium in the grey market, as per ipowatch.com